The protein will be manufactured at QSV’s Edmonton facility and is intended for clinical trials. Work on the project is to begin immediately, and will include technology transfer, scale-up and cGMP manufacturing.
Graeme Macaloney, founder, president & CEO of QSV, said: “The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV’s continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer.”